2020

​

 

 

Poly-ICLC, a multi-functional immune modulator for treating cancer

Sultan H, Celis E, Salazar A. (Seminars in Immunology, Jun 2020)

​

Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration.

Sultan H, Celis E et al. (Journal for Immunotherapy in Cancer, Sept 2020)

​

Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.

Mueller S, Okada H et al. (Journal of Clinical Investigation, Aug 2020)

 

Peptide Vaccine Combined Adjuvants Modulate Anti-tumor Effects of Radiation in Glioblastoma Mouse Mode

Tran T, Jung T et al. (Frontiers in Immunology, Jun 2020)

​

Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens.

Arribillaga L, Lasarte JJ (Journal for Immunotherapy in Cancer, Jun 2020)

​

MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma

Engelhard V, Slingluff C et al. (Journal for Immunotherapy in Cancer, May 2020)

​

​

A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial.

Nakajima M, Najano, H et al. (Cancer Immunology, Immunotherapy, Mar 2020)

​

Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

Pavlick A, Bhardwaj N et al. (Cancer Immunology Research, Jan 2020)

​

​

​

2019

​

The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial.

Weed D, Serafini P et al. (Frontiers in Immunology 2019)

​

​

Therapeutic Effect of Irreversible Electroporation in Combination with Poly-ICLC Adjuvant in Preclinical Models of Hepatocellular Carcinoma.

Vivas I, Lasarte JJ et al. (Journal of Vacular and Interventional Radiology 2019)

​

​

Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial.

Saxena M, Miller E et al. (Frontiers in Immunology 2019)

​

​

Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients.

Boydell E, Dutoit V et al. (Cancers 2019)

​

​

Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination.

Hammerich L, Brody J et al. (Nature Medicine 2019)

​

​

Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. 

Migliorini D, Dietrich, PY et al. (Neuro-oncology 2019)

​

​

​

2018

​

The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice  

Sultan H, Celis E et al. (Cancer Immunology, Immunotherapy 2018)

​

​

The efficacy of poly-ICLC against Ebola-Zaire virus (EBOV) infection in mice and cynomolgus monkeys. 

Kende M, Salazar A et al. (Anitviral Research 2018)

​

​

Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Wick W et al. (Nature  2019)

​

​

Trial Watch: Toll-like receptor agonists in cancer immunotherapy.

Smith M, Galuzzi L et al. (Oncoimmunology 2018)

​

​

HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates.

Flamar A, Levy Y et al. (PLoS One 2018)

​

​

Enhancing the immune stimulatory effects of cetuximab therapy through TLR3 signalling in Epstein-Barr virus (EBV) positive nasopharyngeal carcinoma.

Tan L, Lim C et al. (Oncoimmunology 2018)

​

​

Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial.

Kyi C, Bhardwaj N et al. (Clinical Cancer Research; 2018)

​

​

Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice.

Sultan H, Celis E et al. (Cancer Immunology, Immunotherapy; 2018)

​

​

​

1996-2017

​

An immunogenic personal neoantigen vaccine for patients with melanoma.

Ott P, Wu C et al. (Nature 2017)

​

​

A Phase I trial using local regional treatment, nonlethal irradiation, intratumoral and systemic polyinosinic-polycytidylic acid polylysine carboxymethylcellulose to treat liver cancer: in search of the abscopal effect

de la Torre A, Salazar A et al. (Journal of Hepatocellular Carcinoma; 2017)

​

​

Designing therapeutic cancer vaccines by mimicking viral infections.

Sultan H, Celis E et al. (Cancer Immunotherpy; 2017)

​

​

Cytosolic Receptor Melanoma Differentiation–Associated Protein 5 Mediates Preconditioning-Induced Neuroprotection Against Cerebral Ischemic Injury

Gesuete R, Stenzel-Poore M et al. (Stroke; 2016)

​

​

Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial.

Salazar A, Herberman R et al. (Cancer Immunology Research; 2014)

​

​

MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.

Kimura T, Finn O et al. (Cancer Prevention Research; 2013)

​

​

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinicalactivity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.

Okada H, Lieberman F et al. (Journal of Clinical Oncology; 2011)

​

​

Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccinein humans.

Caskey M, Sekaly R, Steinman R et al. (The Journal of Experimental Medicine 2011) 

​

​

A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.

Rosenfeld M, Ye X et al. (Neuro-oncology 2010)

​

​

Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study.

Salazar A, Omaya A et al. (Neurosurgery 1996)